Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 50387
  • calendar_today Published On: Mar, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Pertuzumab

Trastuzumab

Market segment by Application, can be divided into

Combination Therapy

Mono Therapy

Market segment by players, this report covers

Roche

BOC Sciences

LGM Pharma

Biotechnica Pharma Global

KinBio

Merck

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

1.2 Classification of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Type

1.2.1 Overview: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type in 2020

1.2.3 Pertuzumab

1.2.4 Trastuzumab

1.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market by Application

1.3.1 Overview: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Combination Therapy

1.3.3 Mono Therapy

1.4 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size & Forecast

1.5 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast by Region

1.5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region, (2016-2021)

1.5.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2016-2026)

1.5.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2016-2026)

1.5.6 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers

1.6.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints

1.6.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.1.4 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Roche Recent Developments and Future Plans

2.2 BOC Sciences

2.2.1 BOC Sciences Details

2.2.2 BOC Sciences Major Business

2.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.2.4 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 BOC Sciences Recent Developments and Future Plans

2.3 LGM Pharma

2.3.1 LGM Pharma Details

2.3.2 LGM Pharma Major Business

2.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.3.4 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 LGM Pharma Recent Developments and Future Plans

2.4 Biotechnica Pharma Global

2.4.1 Biotechnica Pharma Global Details

2.4.2 Biotechnica Pharma Global Major Business

2.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.4.4 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Biotechnica Pharma Global Recent Developments and Future Plans

2.5 KinBio

2.5.1 KinBio Details

2.5.2 KinBio Major Business

2.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.5.4 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 KinBio Recent Developments and Future Plans

2.6 Merck

2.6.1 Merck Details

2.6.2 Merck Major Business

2.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

2.6.4 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Merck Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Market Share

3.2.2 Top 10 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Market Share

3.2.3 Market Competition Trend

3.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Market Share by Type (2016-2021)

4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2016-2021)

5.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2026)

6.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2026)

6.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country

6.3.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2026)

6.3.2 United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

6.3.3 Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

6.3.4 Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2026)

7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2026)

7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country

7.3.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2026)

7.3.2 Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

7.3.3 France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

7.3.5 Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

7.3.6 Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2026)

8.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2026)

8.3 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region

8.3.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2016-2026)

8.3.2 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8.3.3 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8.3.4 South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8.3.5 India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

8.3.7 Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2026)

9.2 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2026)

9.3 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country

9.3.1 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2026)

9.3.2 Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

9.3.3 Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2026)

10.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2026)

10.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country

10.3.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2026)

10.3.2 Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

10.3.4 UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) by Region (2016-2021)

Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2021-2026)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 9. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. BOC Sciences Corporate Information, Head Office, and Major Competitors

Table 11. BOC Sciences Major Business

Table 12. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 13. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. LGM Pharma Corporate Information, Head Office, and Major Competitors

Table 15. LGM Pharma Major Business

Table 16. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 17. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Biotechnica Pharma Global Corporate Information, Head Office, and Major Competitors

Table 19. Biotechnica Pharma Global Major Business

Table 20. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 21. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. KinBio Corporate Information, Head Office, and Major Competitors

Table 23. KinBio Major Business

Table 24. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 25. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Merck Corporate Information, Head Office, and Major Competitors

Table 27. Merck Major Business

Table 28. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions

Table 29. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) by Players (2019-2021)

Table 31. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Players (2019-2021)

Table 32. Breakdown of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)

Table 33. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Head Office, Products and Services Provided

Table 34. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Mergers & Acquisitions in the Past Five Years

Table 35. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer New Entrants and Expansion Plans

Table 36. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) by Type (2016-2021)

Table 37. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Type (2016-2021)

Table 38. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Type (2021-2026)

Table 39. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021)

Table 40. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Application (2021-2026)

Table 41. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 42. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 43. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 44. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 45. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 46. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 47. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 48. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 49. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 50. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 51. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 52. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 53. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 54. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 55. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 56. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 57. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2016-2021) & (USD Million)

Table 58. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2021-2026) & (USD Million)

Table 59. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 60. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 61. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 62. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 63. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 64. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 65. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 66. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 67. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 68. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 69. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 70. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Picture

Figure 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type in 2020

Figure 3. Pertuzumab

Figure 4. Trastuzumab

Figure 5. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application in 2020

Figure 6. Combination Therapy Picture

Figure 7. Mono Therapy Picture

Figure 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Forecast (2016-2026) & (USD Million)

Figure 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2016-2026)

Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region in 2020

Figure 12. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 13. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 14. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers

Figure 18. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints

Figure 19. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Trends

Figure 20. Roche Recent Developments and Future Plans

Figure 21. BOC Sciences Recent Developments and Future Plans

Figure 22. LGM Pharma Recent Developments and Future Plans

Figure 23. Biotechnica Pharma Global Recent Developments and Future Plans

Figure 24. KinBio Recent Developments and Future Plans

Figure 25. Merck Recent Developments and Future Plans

Figure 26. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Players in 2020

Figure 27. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 28. Global Top 3 Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share in 2020

Figure 29. Global Top 10 Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share in 2020

Figure 30. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 31. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Type in 2020

Figure 32. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share Forecast by Type (2021-2026)

Figure 33. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Application in 2020

Figure 34. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share Forecast by Application (2021-2026)

Figure 35. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2016-2026)

Figure 36. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2016-2026)

Figure 37. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 38. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 39. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 40. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 41. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2016-2026)

Figure 42. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2016-2026)

Figure 43. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 44. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. United Kingdom Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2016-2026)

Figure 50. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2016-2026)

Figure 51. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2016-2026)

Figure 52. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2016-2026)

Figure 59. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2016-2026)

Figure 60. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 61. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2016-2026)

Figure 64. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2016-2026)

Figure 65. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 66. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Methodology

Figure 70. Research Process and Data Source